Safety Registry for Rezdiffra Use During Pregnancy and Breastfeeding
Part of Hormones & metabolism clinical trials.
This registry collects information about the safety of a liver disease medication called Rezdiffra (resmetirom) when used during pregnancy or while breastfeeding. Researchers want to understand if the medication affects the health of pregnant women, babies, and nursing infants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have NASH (a type of fatty liver disease) and took or are taking Rezdiffra
- You took Rezdiffra within 3 days before becoming pregnant and/or during your pregnancy
- You took Rezdiffra while breastfeeding your baby, or your baby is currently nursing
- Your infant is 12 months old or younger
- You can understand and agree to participate in the registry
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking rezdiffra (a liver medication) together with other common diabetes or liver drugs is safe and effective for adults with MASH (fatty liver disease) and moderate-to-severe liver scarring. It may help improve liver health and reduce disease progression.
This study tests a daily pill, resmetirom, to see if it can reduce fat and scarring in the livers of children and teens with MASH, a type of fatty liver disease. It may help improve liver health and prevent further damage.
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
This trial tests a drug called resmetirom for people who have both a type of fatty liver disease (MASH) and a type of heart failure (HFpEF). It aims to see if the drug can help both conditions. You may be able to join if you have both conditions and meet certain health criteria.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.